Artal Group S.A. Vertex Pharmaceuticals Inc Call Options Transaction History

Artal Group S.A.

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2022 May 12, 2022	SELL	$221.42 - $260.97 $22.1 Million - $26.1 Million	-100,000 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$177.01 - $223.45 $17.7 Million - $22.3 Million	-100,000 Reduced 50.0%	100,000 $22 Million
Q3 2021 Nov 12, 2021	BUY	$181.39 - $202.99 $36.3 Million - $40.6 Million	200,000 New	200,000 $36.3 Million
Q2 2018 Aug 10, 2018	SELL	$145.72 - $169.96 $14.6 Million - $17 Million	-100,000 Closed	0 $0
Q1 2018 May 10, 2018	SELL	$151.6 - $177.13 $15.2 Million - $17.7 Million	-100,000 Reduced 50.0%	100,000 $16.3 Million
Q4 2017 Feb 09, 2018	BUY	$137.28 - $155.55 $27.5 Million - $31.1 Million	200,000	200,000 $30 Million

1,724

221M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $105B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.